Travere Therapeutics, Inc.
TVTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $491M | $233M | +110% |
| Operating income | −$62.8M | −$324M | +80.6% |
| Net income | −$25.6M | −$322M | +92.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $225M | $165M | +36.2% |
| Operating income | −$68.1M | $24.9M | |
| Net income | −$52.3M | $25.7M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Travere's revenue in FY2025?
- $491M in FY2025 (Fiscal year ended Dec 31, 2025), +110% vs $233M a year earlier, per its 10-K filed Feb 2026.
- Was Travere profitable in FY2025?
- No: net income was −$25.6M and operating income −$62.8M in FY2025.
- What was Travere's revenue in Q3 2026?
- $225M (+36.2% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.